MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-19-2025
ProPhase Labs Operating Income 2011-2025 | PRPH
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income ProPhase Labs
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 23.6 M | 9.8 M | -2.08 M | -3.24 M | -1.63 M | -3.99 M | -2.66 M | -3.58 M | -7.83 M | 416 K | -1.1 M | -2.74 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 23.6 M | -7.83 M | 414 K |
Quarterly Operating Income ProPhase Labs
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.76 M | -3.89 M | -3.66 M | - | -6.48 M | -7.23 M | -7.63 M | - | -6.48 M | -4.66 M | 875 K | - | 1.95 M | 10.6 M | 16.1 M | - | -3.65 M | -1.45 M | 1.22 M | - | -567 K | 59 K | -812 K | - | -461 K | -1.27 M | -1.04 M | - | -912 K | -264 K | -53 K | - | -902 K | -886 K | -745 K | - | -786 K | -1.32 M | -1.31 M | - | 603 K | -1.57 M | -1.38 M | - | -3.22 M | -3.14 M | -802 K | - | 1.24 M | -1.72 M | 293 K | - | 1.07 M | -1.93 M | -690 K | - | 1.11 M | -983 K | -1.02 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 16.1 M | -7.63 M | -945 K |
Operating Income of other stocks in the Drug manufacturers industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Canopy Growth Corporation
CGC
|
-117 M | $ 1.68 | -3.44 % | $ 181 M |  Canada |
 |
Alimera Sciences
ALIM
|
-1.93 M | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
-244 M | $ 0.74 | -3.53 % | $ 52.6 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-46.4 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-15.3 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.1 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
-19.9 M | - | 10.11 % | $ 58.2 M | USA |
 |
Aurora Cannabis
ACB
|
-283 M | $ 5.1 | -5.59 % | $ 86.3 M | Canada |
 |
Catalent
CTLT
|
-749 M | - | - | $ 11.5 B | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Organogenesis Holdings
ORGO
|
-1.28 M | $ 4.76 | -1.14 % | $ 627 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-469 M | - | - | $ 28.9 M |  Irlanda |
 |
Pacira BioSciences
PCRX
|
-73.4 M | $ 26.64 | 1.33 % | $ 1.23 B | USA |
 |
Emergent BioSolutions
EBS
|
-726 M | $ 12.27 | 7.44 % | $ 628 M | USA |
 |
Evoke Pharma
EVOK
|
-7.43 M | $ 10.97 | 0.14 % | $ 36.7 M | USA |
 |
Athenex
ATNX
|
-70 M | - | -23.39 % | $ 1.76 M | USA |
 |
Rockwell Medical
RMTI
|
-6.67 M | $ 0.88 | -5.2 % | $ 20.5 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-42.4 M | $ 21.43 | 0.3 % | $ 2.04 B |  France |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.71 M | $ 3.52 | -2.07 % | $ 4.37 M | USA |
 |
Evolus
EOLS
|
-34.4 M | $ 7.14 | 1.42 % | $ 443 M | USA |
 |
Harrow Health
HROW
|
431 K | $ 46.39 | -1.43 % | $ 1.51 B | USA |
 |
China Pharma Holdings
CPHI
|
-4.59 M | $ 1.53 | -1.92 % | $ 26.7 M |  China |
 |
Bausch Health Companies
BHC
|
963 M | $ 6.87 | -0.79 % | $ 2.51 B | Canada |
 |
Veru
VERU
|
-36.9 M | $ 2.39 | -1.24 % | $ 322 M | USA |
 |
Lannett Company
LCI
|
-176 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.81 | -5.99 % | $ 402 M | Canada |
 |
cbdMD
YCBD
|
-3.32 M | $ 1.18 | -3.28 % | $ 5.09 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.84 M | $ 3.04 | 20.16 % | $ 42.7 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-55.6 M | - | - | $ 193 M | Canada |
 |
Solid Biosciences
SLDB
|
-130 M | $ 5.77 | -1.79 % | $ 236 M | USA |
 |
PetIQ
PETQ
|
37.1 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
-104 M | $ 4.34 | 6.9 % | $ 131 M | USA |
 |
Perrigo Company plc
PRGO
|
113 M | $ 12.77 | -2.85 % | $ 1.75 B | USA |
 |
Radius Health
RDUS
|
-54.3 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-3.57 M | - | -4.76 % | $ 65.3 M | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.96 | -11.31 % | $ 3.37 M | Canada |
 |
OptiNose
OPTN
|
-22.7 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-40.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
72.7 M | $ 0.64 | -0.91 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-1.37 B | $ 11.19 | -7.9 % | $ 6.92 B | Canada |
 |
TherapeuticsMD
TXMD
|
-8.52 M | $ 1.7 | -2.86 % | $ 17.7 M | USA |
 |
Zomedica Corp.
ZOM
|
-31.6 M | - | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
1.61 B | $ 11.65 | - | $ 14.1 B | USA |